PARADIGM MEDICAL INDUSTRIES, INC.
ROYALTY AGREEMENT
This ROYALTY AGREEMENT ("Agreement") is made and entered into
effective as of this 20th day of June, 2000, by and between PARADIGM MEDICAL
INDUSTRIES, INC. ("Paradigm"), a corporation organized under the laws of the
State of Delaware, and ▇▇▇▇▇▇ ▇▇▇▇▇▇ ("Beneficiary"), a resident of the United
Kingdom.
WHEREAS, pursuant to a Stock Purchase Agreement (the "Purchase
Agreement"), Paradigm is purchasing from Beneficiary all of the issued and
outstanding shares of Ocular Blood Flow, Ltd., a United Kingdom registered
limited company ("Ocular"), and this Agreement is being executed as of the
Closing Date of said Purchase Agreement (the "Closing Date");
WHEREAS, the principal business of Ocular is the manufacturer
and sale of a product known as a tonometer or blood flow analyzer ("Blood Flow
Analyzer");
WHEREAS, Ocular owns patents and patent applications covering
the Blood Flow Analyzer in the countries of the United States of America, the
United Kingdom, and the European Economic Community (the "Protected Countries"
and the "Patents", respectively); and
WHEREAS, the parties have agreed that Beneficiary shall
receive royalties in respect to the sale of Blood Flow Analyzers by Paradigm or
its subsidiaries, affiliated companies or licensees in accordance with the terms
and provisions of this Agreement.
NOW, THEREFORE, in consideration of the mutual covenants and
promises contained herein, the parties hereto agree as follows:
TERMS OF AGREEMENT
Section 1 - Royalty
--------------------
1.1 In consideration of the Purchase Agreement, Paradigm
agrees to pay to Beneficiary during the Term (as defined in Section 9.1 hereof)
of this Agreement a Royalty of ten percent (10%) of Net Sales of Blood Flow
Analyzers, including work station units, sold by Paradigm (or its subsidiaries,
affiliated companies, or licensees).
1.2 Blood Flow Analyser is the term most commonly used in the
United States of America. Outside of the USA a Blood Flow Analyser is most
commonly known as an OBF Tomometer. A Blood Flow Analyser "work station unit"
comprises a keratometer type base unit on which is mounted an integrated unit of
probe holder and fixation mirror.
1.3 For purposes of this Agreement, "Net Sales" shall mean the
gross amount collected by Paradigm from purchasers of Blood Flow Analyzers less
1
any amounts rebated or refunded to the purchasers. In the event a Blood Flow
Analyzer is sold separately for less than $6,000, the amount which shall be
included in Net Sales in respect to such Blood Flow Analyzer for purposes of
computing Royalties under Section 1.1 shall be U.S. $6,000. In the event a Blood
Flow Analyzer is not sold separately but is sold as part of a sale of a package
including other instruments and/or accessories (the "Package"), then the amount
which shall be included in Net Sales in respect to such Blood Flow Analyzer for
purposes of computing Royalties under Section 1.1 shall be the greater of (i)
the portion of the sales price, if any, specifically allocated to the Blood Flow
Analyzer in the Package sale, or (ii) U.S. $6,000. In no event, however, shall
the Royalty payable in respect to the sale of a Blood Flow Analyzer be less than
U.S. $600.
1.4 Royalties shall be payable on a calendar quarterly basis.
Within thirty (30) days following the close of each calendar quarter, Paradigm
shall provide to Beneficiary a written report setting forth the Net Sales of
Blood Flow Analyzers that Paradigm collected during said quarter. Payment of the
Royalties, if any, for said calendar quarter shall accompany such report.
1.5 Paradigm shall keep and maintain complete and accurate
records of the transactions underlying the reports to be furnished hereunder.
All books of accounts and records shall be kept available for at least two (2)
years from the date of the report to which they relate. Beneficiary may, at
Beneficiary's expense and on ninety (90) days' advance written notice to
Paradigm, conduct an annual audit of Paradigm's books of accounts and records
relating to the reports to be furnished hereunder. Such audit shall be conducted
during regular business hours at a mutually agreeable time and place and shall
not materially interfere with the conduct of Paradigm's business. The rights and
obligations of the parties pursuant to this Section 1.5 shall survive the
expiration of this Agreement or the termination of this Agreement.
Section 2 - New Developments.
-----------------------------
2.1 Paradigm agrees to furnish to Beneficiary twelve (12) of
the latest model Blood Flow Analyzers each year for the five (5) years following
the date of this Agreement with the first group of 12 units to be delivered one
year from the Closing Date. Beneficiary agrees to use the units for research and
sales support/promotion services but not for resale. As a condition to
Paradigm's obligation to furnish said Blood Flow Analyzers, Beneficiary shall
provide the following information to Paradigm: (a) Prior to the delivery of the
first group of 12 units, Beneficiary shall give Paradigm a detailed written plan
of the uses to which he intends to put such units, and (b) at the end of each
subsequent year, Beneficiary shall give Paradigm a detailed written report of
the uses to which units were put during the preceding year including the results
of research and shall give a detailed written plan for the next year of the uses
to which he intends to put previously delivered units and the units to be
delivered at that time.
2.2 Paradigm (or its subsidiary, Ocular) shall own all
modifications, improvements and developments to the Blood Flow Analyzers whether
2
made by Beneficiary or by Paradigm or whether made by them jointly, subject to
the duty to pay Royalties in respect to Net Sales generated from sales
incorporating such modifications, improvements and developments. The parties
agree to perform such acts and execute such documents as may be required to
achieve the intent of this Section 2.2.
Section 3 - Warranties and Representations
------------------------------------------
3.1 Each party represents to the other party and warrants that
such party has all of the requisite power and authority to enter into this
Agreement and to perform each and every term, provision, and obligation of this
Agreement and that neither the execution nor delivery of this Agreement shall
conflict with or result in a breach of the terms, provisions, or obligations of,
or constitute a default under, any other agreement or instrument under which
such party is obligated.
Section 4 - Protection of Beneficiary
-------------------------------------
4.1 Paradigm agrees to use its best efforts to market the
Blood Flow Analyzers on a profitable basis.
4.2 Paradigm shall use its best efforts to maintain the
Patents in the Protected Countries for the maximum time available and shall seek
patent protection for Blood Flow Analyzers in other countries where such
protection is available and it is commercially expedient to do so.
4.3 Any sale, assignment, encumbrance, license or other
disposition by Paradigm of its interest in this Agreement or in the Patents
shall be subject to the rights of ▇▇▇▇▇▇ under this Agreement including, but not
limited to, his right to receive royalties pursuant to the terms of Section 1.1,
and Paradigm agrees to obtain the written agreement of the person or entity
receiving such disposition that they are assuming and agreeing to be bound by
the provisions of this Agreement.
Section 5 -Taxes
----------------
5.1 Beneficiary shall be solely responsible for the payment
and discharge of any taxes, withholdings, or duties imposed by any government or
governmental agency relating to any Royalties paid to him under this Agreement.
Paradigm may, at its option, deduct from the Royalties set forth in Section 1 of
this Agreement, an amount equal to such taxes, withholdings, or duties.
3
Section 6 - Notices
-------------------
6.1 All notices, demands, and other communications under this
Agreement shall be in writing and shall be transmitted by United States or
United Kingdom certified or registered mail, postage prepaid, or by reputable
private express courier, or by telex or telegram or by facsimile transmission to
the parties at the following locations or facsimile numbers:
(a) In the case of Paradigm:
PARADIGM MEDICAL INDUSTRIES, INC.
▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇ ▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇
Facsimile Number: (▇▇▇) ▇▇▇-▇▇▇▇
(b) In the case of Beneficiary:
▇▇▇▇▇▇ ▇▇▇▇▇▇
Ocular Blood Flow, Ltd.
▇▇▇▇ ▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇ Beuttell Way, Malmesbury
▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇
Facsimile Number: 011 441 666 823 763
The parties hereto may give written notice of change of address and, after such
notice has been received, any notice or request shall thereafter be given to
such party at the changed address.
Section 7 - Applicable Law
--------------------------
7.1 The validity and interpretation of this Agreement shall be
governed by and enforced and interpreted under and in accordance with the laws
of Utah as such law shall from time to time be in effect.
Section 8 - Attorneys Fees
--------------------------
8.1 In the event there is a default under this Agreement and
it becomes reasonably necessary for any party to employ the services of an
attorney, either to enforce or terminate this Agreement, with or without
litigation, the losing party or parties to the controversy arising out of the
4
default shall pay to the successful party or parties reasonable attorneys fee
and, in addition, such costs and expenses as are incurred in enforcing or in
terminating this Agreement.
Section 9 - Term
----------------
9.1 This Agreement shall remain in effect for a period of
twenty (20) years from the Closing Date. At the end of the Term, this Agreement
shall terminate and no Royalties shall be payable in respect to Net Sales
realized after such termination.
Section 10 - General Provisions
-------------------------------
10.1 The parties hereto have read this Agreement and agree to
be bound by all its terms. The parties further agree that this Agreement shall
constitute the complete and exclusive statement of the Agreement between them
and supercedes all proposals, oral or written, and all other communications
between them.
10.2 No agreement changing, modifying, amending, extending,
superceding, or discharging this Agreement or any provisions hereof shall be
valid unless it is in writing and is signed by a duly authorized representative
of the party or parties to this Agreement.
10.3 The provisions of this Agreement are severable, and in
the event that any provision of this Agreement shall be held to be invalid,
illegal, or unenforceable, the validity, legality, and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby.
10.4 The failure of any of the parties hereto to enforce any
of the provisions of this Agreement or any rights with respect thereto or the
failure to exercise any election provided for herein, shall in no way be
considered a waiver of such provisions, rights or elections or in any way affect
the validity of this Agreement. No term or provision hereof shall be deemed
waived and no breach excused, unless such waiver or consent shall be in writing
and signed by the party claimed to have waived or consented. The failure by any
of the parties hereto to enforce any of said provisions, rights, or elections
shall not preclude or prejudice such party from either enforcing or exercising
the same or any other provisions, rights, or elections which it may have under
this agreement. Any consent by any party to, or waiver of, a breach of this
Agreement by the other party (whether expressed or implied) shall not constitute
a consent to, a waiver of, or excuse of different or substitute breach. All
remedies herein conferred upon any party shall be cumulative and no one shall be
exclusive of any other remedy conferred herein by law or equity.
10.5 Paradigm and Beneficiary, except as provided herein, each
shall bear all costs and expenses incurred in the performance of their
respective duties under this Agreement.
5
10.6 This Agreement shall be binding not only upon the parties
hereto, but also upon, without limitation thereto, their heirs, successors, and
assigns.
10.7 There shall be no liability on either party on account of
any loss, damage, or delay occasioned or caused by strikes, riots, fires,
insurrection, or the elements, embargoes, failure of carriers, acts of God or of
the public enemy, compliance with any law, regulation, or other governmental
order, or any other cause beyond the control of either party, whether or not
similar to the foregoing.
10.8 Headings used in the Agreement are for reference purposes
only and shall not be deemed a part of this Agreement.
10.9 This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original, all of which
constitute one and the same Agreement.
IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be duly executed as of the date first mentioned above.
PARADIGM:
PARADIGM MEDICAL INDUSTRIES, INC.
By:_______________________________
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, President and
Chief Executive Officer
BENEFICIARY:
----------------------------------
▇▇▇▇▇▇▇ ▇▇▇▇▇▇
6
